‘Amazing’ new lung cancer treatment 40% more effective than standard amid ‘golden age’ of cancer research
NY Post
A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for over 40% longer than previously possible, a wide-ranging trial funded by pharmaceutical giant Janssen showed.
Doctors are hailing the breakthrough as “amazing.”
Lung cancer kills roughly 1.8 million people per year. The insidious disease is known for very low survival rates, particularly in those in advanced stages.
The Guardian reported that a group of patients in that precarious state were given a cocktail of amivantamab, a monoclonal antibody, and lazertinib, a tyrosine kinase inhibitor — keeping them alive and progression-free for an average of 23.7 months.
Sufferers who received the standard treatment, a drug called osimertinib, averaged 16.6 months of progression-free survival, the outlet revealed.
The findings come as experts reportedly hail a “golden age” of cancer research that is leading to better comprehension and better treatment methods.
